A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
This clinical trial tests an experimental medication called BAY2927088 for adults with advanced solid tumors that have a specific genetic change called a HER2 mutation. Researchers want to see if this oral pill can successfully block the abnormal proteins that help cancer cells grow and spread.
You may be able to join if you are 18 or older, have an advanced solid tumor (such as breast, colon, bladder, or uterine cancer) that has spread, and have already tried standard treatments. Participants must have the specific HER2 gene mutation, and people with lung cancer are not eligible for this study.
Participants will take the study medication as a daily pill in repeating 3-week cycles for as long as it is helpful and safe. Throughout the trial, you will have regular check-ups, imaging scans, heart monitoring, and blood or urine tests to see how your body responds to the treatment.
This study is currently recruiting participants at multiple locations across the United States, including sites in Alabama, California, and Florida.
- 1Testing an experimental targeted pill called BAY2927088 for various advanced solid tumors with HER2 mutations.
- 2Open to adults 18 and older who have tried standard treatments and do not have lung cancer.
- 3Involves taking daily pills in 3-week cycles alongside regular health checks and imaging scans.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.